Precision oncology and systemic targeted therapy in Pseudomyxoma Peritonei.
Jordi Martínez-QuintanillaDébora CabotDoménico SabiaOriol ArquésJordi VergésIrene ChicoteLana BijelicLaia CabellosAnna M AlcántaraMaria Isabel Ramos BernadóPedro BarriosOriol CrusellasLina M PalacioJuan-Antonio C SerranoJorge BarriusoJuan J JiménezPau M Muñoz-TorresLara NonellRaquel FloresEnzo MedicoMarcello GuaglioJavier RosElena Elez FernandezJosep TaberneroOmer AzizMarcello DeracoHéctor G PalmerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our study demonstrates for the first time that systemic targeted therapies can effectively control PMP tumors. BRAF signaling pathway inhibition represents a new therapeutic opportunity for BRAFV600E PMP patients who have a poor prognosis. Importantly, our present data and collection of preclinical models pave the way for evaluating the efficacy of other systemic targeted therapies toward extending the promise of precision oncology to PMP patients.